Abstract
This article has been withdrawn because Professor Shauna Culshaw was erroneously included as an author.
References
Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008; 112:1557-1569 https://doi.org/10.1182/blood-2008-05-078154
Medicines, Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf (accessed March 2022)
Royal College of Physicians. National clinical audit of biological therapies – Annual report 2016. https://www.rcplondon.ac.uk/projects/outputs/national-clinical-audit-biological-therapies-annual-report-2016 (accessed March 2022)
NICE. Platelets – abnormal counts and cancer. 2021. https://cks.nice.org.uk/topics/platelets-abnormal-counts-cancer/ (accessed March 2022)
Scottish Dental Clinical Effectiveness Programme (SDCEP). Management of dental patients taking anticoagulants or antiplatelet drugs. 2015. http://www.sdcep.org.uk/published-guidance/anticoagulants-and-antiplatelets/ (accessed January 2022)
Radfar L, Ahmadabadi RE, Masood F, Scofield RH. Biological therapy and dentistry: a review paper. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120:594-601 https://doi.org/10.1016/j.oooo.2015.07.032
Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016; 2:151-153 https://doi.org/10.1016/j.ijwd.2016.09.003
Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012; 33:1339-1347 https://doi.org/10.1038/aps.2012.51
Bingham CO, Moni M. Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions. Curr Opin Rheumatol. 2013; 25:345-353 https://doi.org/10.1097/BOR.0b013e32835fb8ec
Savioli C, Ribeiro AC, Fabri GM Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol. 2012; 18:180-184 https://doi.org/10.1097/RHU.0b013e31825828be
NICE. Final appraisal determination adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. 2008. http://www.nice.org.uk/guidance/gid-tag393/documents/rheumatoid-arthritis-adalimumab-etanercept-and-infliximab-sequential-use-final-appraisal-determination3 (accessed January 2022)
NICE. Infliximab. 2022. https://bnf.nice.org.uk/drug/infliximab.html (accessed March 2022)
Scottish Dental Clinical Effectiveness Programme (SDCEP). Oral health management of patients at risk of medication-related osteonecrosis of the jaw. 2017. http://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/ (accessed January 2022)
Nifosì AF, Zuccarello M, Nifosì L Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg. 2019; 45:3-8 https://doi.org/10.5125/jkaoms.2019.45.1.3
Cassoni A, Romeo U, Terenzi V Adalimumab: another medication related to osteonecrosis of the jaws?. Case Rep Dent. 2016; 2016 https://doi.org/10.1155/2016/2856926
Biologics and Dentistry: Implications for Dental Treatment and Patient Management [WITHDRAWN]
From Volume 49, Issue 4, April 2022 | Pages 348-350